Presiding over the upward trajectory of Eli Lilly over the last eight years is paying off nicely for CEO David Ricks. | ...

CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the ...

The company also launched new 7.5-mg and 10-mg single-use vials, which cost $499 when refilled every 45 days through Eli Lilly's new "Zepbound Self Pay Journey Program.". Eli Lilly's fourth ...

Eli Lilly (Lilly) has agreed to make a $10m ... aimed at treating inflammatory bowel disease (IBD). Under the deal, Lilly will pay $10m upfront and up to $50m in milestones, as per a Securities ...

Eli Lilly is buying a new drug and lowering prices on an existing one. GLP-1 weight loss drug Zepbound is getting cheaper. This will make Lilly's product relatively more attractive, and help to ...

The company said its own self-pay program removes third-party supply chain entities, "allowing patients to access savings directly outside of insurance." Eli Lilly is expanding the supply and ...

According to Eli Lilly, the company is: Lowering the price of the 2.5 mg dose to $349 per month. Lowering the price of the 5 mg dose to $499 per month. Launching the Zepbound Self Pay Journey Program, ...

(RTTNews) - Eli Lilly and Company (LLY) has launched 7.5 mg and 10 mg Zepbound single-dose vials for $499 under the Zepbound Self Pay Journey Program, making the obesity medication more affordable ...

Eli Lilly has lowered the price of its weight-loss drug Zepbound for patients paying out of pocket and introduced two new available vial doses.

Eli Lilly (LLY) CEO David Ricks got a 10% raise in 2024, as a surge in demand for weigh-loss drugs has propelled the pharma giant into the most valuable pharmaceutical company in the world.